Skip to main content

Advertisement

Table 5 QALY (quality-adjusted life-year) accrual associated with the three cohorts over 9 years (discounted at 3 % annually)

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Model TTZ cohort TT cohort Control cohort [25]
First-eye model 7.202 7.050 6.749
Second-eye model 5.269 5.016 4.616
Combined-eye model 6.546 6.384 6.024
  1. TTZ triple therapy with zeaxanthin, TT triple therapy
  2. Combined-eye model = 66 % first-eye model and 34 % second-eye model, Zeaxanthin = Zx